Consensus Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E. Other stock markets 16:30:00 17/06/2024 BST			After market 19:12:21
16.95 ^USD	-3.14%		17.18	+1.39%

06-14	Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...
06-14	Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	MT

Evolution of the average Target Price on Teva Pharmaceutical Industries Limited

Price target over the last 5 years

History of analyst recommendation changes

f3404bd5e488370bb0e9f24ca2e5d.XCPU_h9RI781fjyx9psJwigATs7nFPD2OGIaH1lqMpo.MhCGk29octlENnjbzvM58H5iBqrRYKPbQhpvaiEFSOw9cYezQDtM51Y5Vw~aee6221c39ee0d01fb89147ebdda4eee

Analyst Recommendations on Teva Pharmaceutical Industries Limited

Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	06-05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	05-17	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	05-15	MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	05-13	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	03-08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	02-12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	01-29	MT
Teva: share price up, broker in support	01-23	CF
TEVA : Jefferies raises its recommendation	01-23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	01-23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	01-12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	01-03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	12-18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	11-27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	06/07/23	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	18/05/23	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	09/02/23	MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10	19/01/23	MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10	04/11/22	MT
Jefferies Assumes Teva Pharmaceutical Industries at Buy with $10 Price Target	21/10/22	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $11 From $13, Maintains Buy Rating	14/10/22	MT
BofA Securities Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $10	05/08/22	MT
ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...	17/05/22